Complete Guide to GLP-1 Medication Costs in 2026

The Bottom Line

GLP-1 medications cost anywhere from $149/month (compounded via telehealth) to $1,350/month (brand-name Wegovy at retail). Your actual price depends on three things: which drug, whether you have insurance, and which access path you use.

This guide breaks down every option so you can find the lowest cost for your situation.

Every GLP-1 Medication: What You’ll Actually Pay

Brand-Name Injectable GLP-1s

*Mounjaro’s $25 copay card only works with qualifying commercial insurance — not for uninsured patients.

Oral GLP-1s (The New Option)

Compounded GLP-1s via Telehealth

Important note on compounded GLP-1s: As of February 2026, the FDA officially ended the semaglutide shortage declaration. Compounding pharmacies can now only provide compounded semaglutide to patients with documented medical needs (allergies, unique dosing requirements) where the FDA-approved product isn’t suitable. This may affect availability — ask your telehealth provider about current access.

How to Get the Lowest Price: Decision Tree

Step 1: Check your insurance If your plan covers GLP-1s for your indication (diabetes or weight loss), you may pay as little as $25/month with manufacturer copay cards. Start with your insurance formulary.

Step 2: No insurance coverage? Use manufacturer programs

• Ozempic/Wegovy: NovoCare Pharmacy offers $349/mo for uninsured patients
• Zepbound: LillyDirect Self Pay Journey offers $299–$449/mo depending on dose
• Wegovy Pill: As low as $149/mo intro pricing through NovoCare

Step 3: Consider telehealth + compounded options If brand-name is still too expensive, telehealth platforms offering compounded versions run $149–$299/mo. Check that the provider uses a licensed 503B compounding pharmacy.

Step 4: Compare providers Prices vary significantly between telehealth platforms even for the same medication. Our provider comparison tool shows current pricing from 8+ verified platforms side by side.

Price Comparison by Access Path

Here’s what the same medication costs through different channels:

Semaglutide (Ozempic/Wegovy)

Tirzepatide (Mounjaro/Zepbound)

Insurance Coverage: What Actually Gets Covered

Commercial Insurance (Employer Plans)

Coverage varies wildly. Some plans cover GLP-1s for both diabetes and weight loss. Others only cover for diabetes. And some don’t cover them at all.

How to check: Call the number on your insurance card and ask: “Does my plan cover [specific drug name] for [your indication]?” Get the answer in writing.

Tip: If your plan covers it for diabetes but not weight loss, and you also have Type 2 diabetes or prediabetes, your doctor may be able to prescribe for the diabetes indication — which happens to also help with weight management.

Medicare

Medicare Part D historically didn’t cover GLP-1s for weight loss (only for diabetes). That’s changing:

• July 2026: The Medicare GLP-1 Bridge Program launches, covering anti-obesity medications for beneficiaries with obesity and cardiovascular disease
• January 2027: The BALANCE Model expands this further

Read our state-by-state insurance coverage guide for eligibility details and how to prepare.

Medicaid

Coverage varies by state. Currently, about half of state Medicaid programs cover at least one GLP-1 for weight management. Check your state’s coverage in our state-by-state guide.

Cost-Saving Strategies

1. Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly offer significant discounts for uninsured and underinsured patients:

• Novo Nordisk NovoCare: $349/mo for Ozempic and Wegovy (injectable), $149–$299/mo for Wegovy Pill
• Eli Lilly LillyDirect: $299–$449/mo for Zepbound depending on dose

2. Pharmacy Discount Cards

GoodRx, SingleCare, and RxAssist can sometimes beat manufacturer pricing, especially for lower doses. Always compare.

3. Prior Authorization Appeal

If your insurance denies coverage, appeal. Many initial denials are overturned. Our insurance coverage guide walks you through the process step by step.

4. Oral Wegovy

The newly approved Wegovy pill (oral semaglutide for weight loss) starts at $149/mo through NovoCare — significantly cheaper than the injection. If the pill format works for you, this is currently the best deal on a brand-name GLP-1.

5. Consider Newer Entrants

As competition increases (Foundayo expected mid-2026, generics starting 2031–2033), prices will likely continue dropping. Eli Lilly has already cut Zepbound pricing through LillyDirect in response to competitive pressure.

What’s Coming: The GLP-1 Price Outlook

2026: Oral Wegovy, the Medicare Bridge Program, and Foundayo (orforglipron) — FDA-approved in April 2026 at $149–$349/mo — are the three biggest cost developments this year.

2027: Novo Nordisk has committed to US price cuts (target: $675/mo for Wegovy). The BALANCE Model further expands Medicare coverage.

2031–2033: US patents on semaglutide and tirzepatide begin expiring. Generic competition will dramatically reduce costs — Canadian generics may arrive sooner.

The overall trend is clear: GLP-1s are getting cheaper. But for the next 1–2 years, using the right access path makes a massive difference.

Frequently Asked Questions

What’s the cheapest way to get a GLP-1 in 2026?

The cheapest FDA-approved GLP-1 medication in 2026 is the Wegovy Pill (oral semaglutide) through Novo Nordisk’s NovoCare savings program at $149 per month for the starter dose — no insurance required. Foundayo (orforglipron), Eli Lilly’s new oral GLP-1 approved in April 2026, also starts at $149/month with savings card pricing as low as $25/month for eligible patients. For patients with commercial insurance that covers anti-obesity medications, copays through manufacturer savings cards can drop to $0–25/month for most branded GLP-1s. Compounded semaglutide through telehealth providers historically cost $149–299/month, but availability has decreased significantly since the FDA ended the semaglutide shortage declaration in February 2026. If you’re uninsured, the manufacturer self-pay programs — NovoCare for Novo Nordisk products and LillyDirect for Eli Lilly products — consistently offer the lowest verified prices. Use our cost calculator to compare your specific situation across all access pathways.

Why do GLP-1 medications cost so much?

Brand-name GLP-1 medications cost $850–1,350 per month at retail because they’re protected by patents that prevent generic competition until 2031–2033, giving manufacturers pricing exclusivity. Developing these drugs required billions in R&D — Novo Nordisk invested over a decade in the SUSTAIN, STEP, and SELECT clinical trial programs for semaglutide alone. Pharmaceutical companies also price based on perceived value: since GLP-1s reduce cardiovascular events by 20% (per the SELECT trial) and can eliminate the need for bariatric surgery ($20,000–35,000), manufacturers argue the medications pay for themselves. The U.S. lacks the government price negotiation mechanisms that other countries use — the same medications cost 50–80% less in Canada, the UK, and Europe. The Inflation Reduction Act is beginning to change this for Medicare, but commercial pricing remains market-driven. Competition is the most likely driver of lower prices: Foundayo’s launch at $149/month and Novo Nordisk’s announced 2027 price cut for Wegovy (target: $675/month) signal that the price ceiling is finally cracking.

Are compounded GLP-1s safe?

Compounded GLP-1 medications from licensed 503B outsourcing facilities undergo batch-level quality testing including potency, sterility, and endotoxin checks — but they are not FDA-approved products and don’t go through the same manufacturing validation as branded drugs. Safety concerns have been real: in 2024–2025, the FDA issued warnings about some compounded semaglutide products containing semaglutide sodium salt, a different molecular form than the approved acetate salt, with unknown pharmacokinetic properties. Dosing variability between compounding pharmacies has also been documented, with some batches testing outside of labeled concentrations. Since February 2026, when the FDA ended the semaglutide shortage declaration, 503B compounders can only produce semaglutide for patients with documented medical needs (allergies, unique dosing requirements) — not for general weight loss. If you’re currently using compounded semaglutide, verify your pharmacy holds USP 797/800 accreditation, ask for third-party potency testing certificates, and consider switching to a branded option like the Wegovy Pill ($149/month) now that the price gap has narrowed significantly.

Will Medicare cover GLP-1 for weight loss?

Yes — Medicare coverage for GLP-1 weight-loss medications is expanding in two phases. Starting July 2026, the Medicare GLP-1 Bridge Program will cover anti-obesity medications for Part D beneficiaries who have both obesity (BMI ≥30) and established cardiovascular disease (prior heart attack, stroke, or diagnosed coronary artery disease). This program was accelerated after the SELECT trial demonstrated that Wegovy reduces major adverse cardiac events by 20% in this population. In January 2027, the BALANCE Model expands coverage further to additional Medicare beneficiaries with obesity and weight-related comorbidities beyond cardiovascular disease, including Type 2 diabetes, sleep apnea, and hypertension. Prior to these programs, Medicare was federally prohibited from covering weight-loss drugs under Part D — a restriction that left over 12 million Medicare beneficiaries with obesity without pharmaceutical access. Eligibility criteria, prior authorization requirements, and preferred formulary drugs vary by specific Part D plan. Check our state-by-state insurance coverage guide for details on how to prepare your documentation before enrollment opens.

How much does GLP-1 cost per year?

Annual GLP-1 medication costs range from approximately $1,788 to over $16,200 depending entirely on which access pathway you use — a 5–9x difference for the same active ingredient. At the low end, the Wegovy Pill through NovoCare costs $1,788/year ($149/month starter dose), and Foundayo with Eli Lilly’s savings card runs as low as $300/year ($25/month). Mid-range options include NovoCare self-pay for injectable Wegovy at $4,188/year ($349/month) and LillyDirect for Zepbound at $3,588–5,388/year ($299–449/month depending on dose). At retail without insurance or discount programs, costs reach $10,200–16,200/year — with Saxenda at the highest end near $17,160/year. For commercially insured patients with GLP-1 coverage, annual out-of-pocket costs with manufacturer copay cards typically fall between $0–300/year (copays of $0–25/month). The access pathway you choose matters more than which specific drug you take. Use our cost calculator to model your specific annual cost across all available options.

When will GLP-1 generics be available?

Generic versions of the major GLP-1 medications will begin entering the U.S. market between 2031 and 2033 as key patents expire. Semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) has primary U.S. patents expiring in 2031–2032, while tirzepatide (Mounjaro, Zepbound) patents extend through approximately 2033. However, pharmaceutical companies often file additional patents to extend exclusivity — a practice called “patent thickets” — so actual generic entry dates may shift. Based on historical patterns from other biologic medications, generic GLP-1s are expected to cost 70–90% less than current brand-name prices, potentially bringing monthly costs below $100. Canadian and international generic versions may arrive 1–2 years before U.S. generics due to different patent frameworks. In the meantime, competition from newer drugs is already pushing prices down: Foundayo launched at $149/month in April 2026, and Novo Nordisk has committed to cutting Wegovy’s price to $675/month by 2027. The practical advice: don’t wait for generics if you need treatment now — use manufacturer programs and our cost calculator to find affordable access today.